Diabetes and Blood Glucose Disorders Under Anti-PD1

Journal of Immunotherapy
Quentin MagisJean-Jacques Grob

Abstract

Acute type 1 diabetes (AD1) is a rare but definitive immune-related adverse event associated with anti-PD1. Most of the reported cases are close to what has been described as "fulminant type 1 diabetes." We sought to determine whether anti-PD1 could impair glycoregulation and whether occurrence of AD1 could be anticipated by prior glycemic changes. Fasting glycemia collected before, under, and after treatment in melanoma patients treated with anti-PD1 over a period of 36 months were retrospectively analyzed. Glycemic trend analyses were performed using linear regression analysis. In total, 1470 glucose values were monitored in 163 patients treated for a mean duration of 5.96 months. Three patients developed an AD1 (1, 84%). Two other cases were observed in the same period in a still-blinded trial of anti-PD1 versus ipilimumab. All cases of AD1 occurred in patients with a normal pretreatment glycemia, and there was no detectable drift of glycemia before ketoacidosis onset. In 4 of 5 cases of AD1, the HLA subgroups were DRB01* 03 or 04, known to increase type 1 diabetes risk in the general population. In the 28 patients with preexisting type 2 diabetes, there was a slight trend for glycemia increase with anti-PD1 infusions (0.05 ...Continue Reading

References

Nov 29, 2001·Diabetologia·C Lévy-MarchalUNKNOWN EURODIAB ACE Study Group. Europe and Diabetes
Jul 9, 2003·The Journal of Experimental Medicine·Mohammed Javeed I AnsariMohamed H Sayegh
Aug 10, 2005·Proceedings of the National Academy of Sciences of the United States of America·Jian WangTasuku Honjo
Aug 17, 2006·Diabetic Medicine : a Journal of the British Diabetic Association·UNKNOWN DIAMOND Project Group
Dec 21, 2006·Nature Clinical Practice. Endocrinology & Metabolism·Toshiaki Hanafusa, Akihisa Imagawa
Oct 3, 2008·Diabetes & Metabolism·C MoreauB Cariou
Oct 20, 2009·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Simona Cernea, Kevan C Herold
Nov 10, 2011·Diabetes/metabolism Research and Reviews·Akihisa Imagawa, Toshiaki Hanafusa
Jun 5, 2012·The New England Journal of Medicine·Julie R BrahmerJon M Wigginton
Jun 4, 2013·The New England Journal of Medicine·Omid HamidAntoni Ribas
Nov 18, 2014·The New England Journal of Medicine·Caroline RobertPaolo A Ascierto
Dec 30, 2014·Diabetes & Metabolism·E EschwegeM-A Charles
Apr 2, 2015·Cancer Immunology, Immunotherapy : CII·Juan Martin-LiberalJames Larkin
Apr 22, 2015·The New England Journal of Medicine·Caroline RobertUNKNOWN KEYNOTE-006 investigators
Jun 28, 2015·The Lancet Oncology·Samantha Bowyer, Paul Lorigan
Jun 28, 2015·Diabetes Care·Mahnaz MellatiIrl B Hirsch
Aug 28, 2015·Diabetes Care·Caroline GaudySophie Béliard
Apr 18, 2016·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Lars HofmannLucie M Heinzerling
Nov 3, 2016·Journal of Diabetes Investigation·Masahide OkamotoHirotaka Shibata
Jun 15, 2016·The Tohoku Journal of Experimental Medicine·Yuka MiyoshiYu Oyama
Jun 24, 2016·The Journal of Dermatology·Yukiko TeramotoAkifumi Yamamoto
Jul 2, 2016·JAMA Oncology·Claire F FriedmanMichael A Postow
Oct 4, 2016·International Journal of Hematology·Wataru MunakataKensei Tobinai
Dec 27, 2016·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Yuko UsuiKoichi Goto

❮ Previous
Next ❯

Citations

Aug 1, 2020·Oncotarget·Karen YunSandip Pravin Patel
Aug 20, 2019·Acta Diabetologica·Lucien MarchandChristine Cugnet-Anceau
Jul 18, 2020·Clinical Medicine : Journal of the Royal College of Physicians of London·Angelos KyriacouPunith Kempegowda
Sep 20, 2020·Life·Taku FujimuraSetsuya Aiba
Jan 8, 2021·Cancer Immunology, Immunotherapy : CII·Noha Abdel-WahabMaria E Suarez-Almazor

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.

Related Papers

Medical Science Monitor : International Medical Journal of Experimental and Clinical Research
Mariko SueNaoki Hiroi
The Nurse Practitioner
Carrie Palmer, Ann Jessup
© 2022 Meta ULC. All rights reserved